PEOPLE - Changes at VenPro:
This article was originally published in Clinica
Rob Michiels has resigned from his dual position as president and chief operating officer of Interventional Technologies and managing director of the US cardiovascular device company's European subsidiary to join the California-based life sciences company VenPro. Other organisational changes within the company include Dr William Crawford retiring in August as vice-president of medical and regulatory affairs; and the promotion of Michael Klicpera to vice-president of legal and regulatory affairs, Dolf Meewis to vice-president of international sales and marketing and Ed Pannek to managing director of Interventional Technologies Europe.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.